Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of IMC-RON8 in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01119456
Recruitment Status : Completed
First Posted : May 7, 2010
Results First Posted : February 15, 2019
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
A dose escalation study to determine the maximum tolerated dose of IMC-RON8 in participants with solid tumors. Participants can either be dosed once a week, or once every other week.

Condition or disease Intervention/treatment Phase
Cancer Biological: IMC-RON8 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Anti-Ron Receptor Monoclonal Antibody IMC-RON8 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
Study Start Date : May 2010
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Arm Intervention/treatment
Experimental: IMC-RON8
A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
Biological: IMC-RON8

5 milligrams per kilogram (mg/kg) intravenously (IV)

Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.

Cohort 1

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

10 mg/kg IV

Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.

Cohort 2

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

15 mg/kg IV

Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.

Cohort 3

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

15 mg/kg IV

Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.

Cohort 4

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

20 mg/kg IV

Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.

Cohort 5

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

25 or 30 mg/kg IV

Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.

Cohort 6

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

30, 35, or 40 mg/kg IV

Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.

Cohort 7

Other Names:
  • Narnatumab
  • LY3012219

Biological: IMC-RON8

20 or 25 mg/kg IV

Once every week for each 4-week treatment cycle, for a total of four doses per cycle.

Cohort 8

Other Names:
  • Narnatumab
  • LY3012219




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of IMC-RON8 [ Time Frame: Baseline through end of study treatment (up to 48 weeks) ]
    The MTD was the previous dose level to that in which 2 of 6 participants experienced dose-limiting toxicities (DLTs). DLTs were defined as any of the following events: Grade 4 neutropenia lasting >7 days; any Grade 3 or 4 neutropenia complicated by fever ≥38.5 degrees Celsius or infection, Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia complicated by hemorrhage; Grade 3 hepatic toxicity; or any Grade 3 or 4 nonhematologic toxicity (excluding alopecia, fatigue, anorexia, nausea, and vomiting that is controlled with antiemetics).


Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of IMC-RON8 [ Time Frame: First and fourth or fifth infusion: Predose, immediately postdose through 168 or 336 hours postdose ]
    The Cmax of IMC-RON8 following the first and multiple IV infusions (the fourth infusion for the qw treatment regimen and the fifth infusion for the q2w treatment regimen) is reported. PK samples were collected per protocol and individual sampling times varied depending on the treatment arm and infusion (first or multiple). The geometric mean and geometric coefficient of variation (%CV) were calculated for treatment arms that had ≥3 participants who had evaluable PK samples for Cmax.

  2. PK: Area Under the Curve (AUC) of IMC-RON8 [ Time Frame: First and fourth or fifth infusion: Predose, immediately postdose through 168 or 336 hours postdose ]
    The AUC from time 0 to the last quantifiable concentration [AUC(0-tlast)] of IMC-RON8 following the first IV infusion is reported along with the AUC for 1 dosing interval (AUC tau). Tau = fourth infusion through 168 hours post infusion for the qw regimen and the fifth infusion through 336 hours post infusion for the q2w regimen. PK samples were collected per protocol and individual sampling times varied depending on the treatment arm and infusion (first or multiple). The geometric mean and geometric coefficient of variation (%CV) were calculated for treatment arms that had ≥3 participants who had evaluable PK samples for AUC(0-tlast) or AUC tau.

  3. Immunogenicity of IMC-RON8 [ Time Frame: Prior to first infusion through study completion (up to 52 weeks) ]
    An immunogenicity assay for IMC-RON8 was not developed due to the decision to not further develop IMC-RON8 based on preliminary results of this study.

  4. Pharmacodynamics: H-Score of Macrophage-Stimulating 1-Receptor-8 (RON8) [ Time Frame: Prior to first infusion through 1 hour post last infusion (end of study treatment, up to 48 weeks) ]
    The expression of RON8 was measured in cell membrane/cytoplasm by immunohistochemistry (IHC) methods that incorporated both intensity and distribution of staining. The H-Score was calculated by summing the percentage of cell staining at each intensity multiplied by the weighted intensity of staining: 0 (no staining), 1+ (weak staining), 2+ (medium staining), 3+ (strongest staining). H-Scores could range from a minimum score of 0 to a maximum score of 300; the maximum score indicated the strongest expression. Pharmacodynamic samples were collected per protocol and individual sampling times varied depending on the treatment group.

  5. Best Overall Tumor Response (Antitumor Activity of IMC-RON8 in the Treatment of Solid Tumors) [ Time Frame: Baseline to measured PD (up to 48 weeks) ]
    Response was defined using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST, v 1.1) criteria. CR was the disappearance of all target and nontarget lesions; and any pathological lymph node (whether target or nontarget) must have had a reduction in short axis to <10 millimeters (mm) and normalization of tumor marker level of nontarget lesions. The disappearance of any intratumoral arterial enhancement in all target lesions was also required. PR was having at least a 30% decrease in sum of longest diameter of target lesions. PD was having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir and the unequivocal progression of existing nontarget lesions. SD was small changes that did not meet the above criteria.


Other Outcome Measures:
  1. Number of Participants Who Died [ Time Frame: Baseline through study completion (up to 52 weeks) ]
    The number of participants who died is reported by cause of death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The participant has histologically-confirmed advanced primary or recurrent solid tumors that have not responded to standard therapy or for which no standard therapy is available
  • The participant has measurable or non-measurable disease
  • The participant has not received major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy within 28 days prior to the first dose of study therapy
  • The participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2
  • The participant has adequate hematologic function
  • The participant has adequate renal function as defined by serum creatinine ≤1.5 times the institutional upper limit of normal (ULN)
  • The participant has a life expectancy >3 months

Exclusion Criteria:

  • The participant has received chemotherapy or therapeutic radiation therapy within 28 days prior to the first dose of study therapy
  • The participant has ongoing toxicities of >Grade 1 associated with any prior treatment
  • The participant has a known sensitivity to monoclonal antibodies or other therapeutic agents, or to agents of similar biologic composition as IMC-RON8
  • The participant has received treatment with any monoclonal antibodies within 6 weeks prior to first dose of study therapy
  • The participant has received treatment with agents specifically targeting the RON ligand or receptor within 6 weeks prior to first dose of study therapy
  • The participant has undergone a major surgical procedure, open biopsy, or experienced a significant traumatic injury within 28 days prior to the first dose of study therapy
  • The participant has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia (well controlled atrial fibrillation is permitted), psychiatric illness/social situations, active bleeding, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • The participant has known or suspected brain or leptomeningeal metastases (participants with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and may not be taking steroids; participants receiving anticonvulsants are eligible)
  • The participant has a serious or nonhealing active wound, ulcer, or bone fracture
  • The participant is currently using or has received a thrombolytic agent within 28 days prior to first dose of study therapy
  • The participant is receiving full-dose warfarin (participants receiving low-dose warfarin to maintain the patency of permanent, indwelling intravenous catheters are eligible if the international normalized ratio is <1.5)
  • The participant is receiving intravenous heparin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01119456


Locations
Layout table for location information
United States, Indiana
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Indianapolis, Indiana, United States, 46202
United States, Michigan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Detroit, Michigan, United States, 48201
United States, New York
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
New York, New York, United States, 10065
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01119456     History of Changes
Other Study ID Numbers: 13958
CP21-0901 ( Other Identifier: ImClone Systems )
I5D-IE-JRCA ( Other Identifier: Eli Lilly and Company )
First Posted: May 7, 2010    Key Record Dates
Results First Posted: February 15, 2019
Last Update Posted: February 15, 2019
Last Verified: October 2018

Keywords provided by Eli Lilly and Company:
Tumors
Macrophage stimulating 1 receptor, human
RON protein
RON receptor protein tyrosine kinase

Additional relevant MeSH terms:
Layout table for MeSH terms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs